• @Blossom Is A Blessing To This Community, Let Us Be A Blessing To Her
    Click Here For More Information
  • Due to excessive bot signups along with nefarious actors we are limiting forum registration. Keep checking back for the register link to appear. Please do not send emails or have someone post to the forum asking for a signup link. Until the current climate changes we do not see a change of this policy. To join the forum you must have a compelling reason. Letting us know what skills/knowledge you will bring to the community along with the intent of your stay here will help in getting you approved.

Blood Expert Says He Found Why Some Covid-19 Vaccines Trigger Rare Clots

Mito

Member
Joined
Dec 10, 2016
Messages
2,484
Scientists world-wide are racing to understand why Covid-19 vaccines from AstraZeneca AZN +0.98% PLC and Johnson & JohnsonJNJ +1.32% are causing rare but potentially deadly blood clots.

Determining the connection would help patients, doctors and health agencies better assess any risks posed by the vaccines and safely calibrate their use. In recent weeks, the U.S., the Canadian province of Ontario and several European countries including Norway and Denmark either paused or completely halted rollouts involving these vaccines.

“Understanding the cause is of highest importance for the next-generation vaccines, because [the novel] coronavirus will stay with us and vaccination will likely become seasonal,” said Eric van Gorp, a professor at Erasmus University in the Netherlands who heads a group of scientists studying the condition.

In Germany, one researcher thinks he has found what is triggering the clots. Andreas Greinacher, a blood expert, and his team at the University of Greifswald believe so-called viral vector vaccines—which use modified harmless cold viruses, known as adenoviruses, to convey genetic material into vaccine recipients to fight the coronavirus—could cause an autoimmune response that leads to blood clots. According to Prof. Greinacher, that reaction could be tied to stray proteins and a preservative he has found in the AstraZeneca vaccine.

Prof. Greinacher and his team has just begun examining Johnson & Johnson’s vaccine but has identified more than 1,000 proteins in AstraZeneca’s vaccine derived from human cells, as well as a preservative known as ethylenediaminetetraacetic acid, or EDTA. Their hypothesis is that EDTA, which is common to drugs and other products, helps those proteins stray into the bloodstream, where they bind to a blood component called platelet factor 4, or PF4, forming complexes that activate the production of antibodies.

The inflammation caused by the vaccines, combined with the PF4 complexes, could trick the immune system into believing the body had been infected by bacteria, triggering an archaic defense mechanism that then runs out of control and causes clotting and bleeding.


Prof. Greinacher has compared the activation of the dormant response—which has been supplanted in the evolution of the human immune system, but still lurks in its foundations—to “awakening a sleeping dragon.”

Prof. John Kelton of McMaster University in Canada, whose outfit runs Canada’s reference lab for testing patients with blood-clotting symptoms after vaccination, said the lab replicated some of Prof. Greinacher’s research and confirmed his findings.

Yet the cause was unclear. “[Prof. Greinacher’s] hypothesis could be right, but it could also be wrong,” Prof. Kelton said.

Prof. Greinacher is working to confirm his theory, hoping to get cooperation from vaccine makers. His team has tested AstraZeneca vaccines and has just received doses from Johnson & Johnson. Greifswald University is now negotiating with the drugmakers about greater access to their vaccine-making processes.

“We strongly support raising awareness of the signs and symptoms of this very rare event, and we are currently exploring a potential collaboration with Dr. Greinacher,” said a Johnson & Johnson spokesman.

AstraZeneca didn’t respond to a request for comment.

The type of clotting observed is known as vaccine-induced immune thrombotic thrombocytopenia, or VITT. Peer-reviewed studies by Prof. Greinacher’s group, as well as from teams at the University of Oslo and University College London have independently confirmed its existence.

Most of the science hubs investigating the clotting issue, first identified in March, are experts in a condition called heparin-induced thrombocytopenia or HIT, which has near-identical symptoms and outcomes to VITT. With HIT, the blood-thinning drug heparin causes clots paired with an abnormal decrease in the blood’s natural clotting agents.

Some scientists think the adenoviruses themselves could play a role in triggering the condition because they have been linked to blood clotting. Others speculate that people affected could have genetic predispositions, or that their immune systems had previously developed the problematic antibody.

Another theory suggested by Prof. van Gorp is that the brief but strong flulike symptoms many recipients report after taking the shot are also causing inflammation that could trigger or exacerbate autoimmune reactions leading to blood clotting.

One reason vaccine-induced clotting might not have been reported in the past is because shots using viral vector technology haven’t been administered at scale. The Russian vaccine Sputnik V and the shot by CanSino Biologics from China use the same technology as AstraZeneca and Johnson & Johnson, but haven’t been linked to the condition so far.

The only similar shot widely administered before the pandemic is one against Ebola by Johnson & Johnson, which was given to at least 60,000 people as of last July.

Clotting occurs between one in 28,000 and one in 100,000, according to European data—extremely rare amid the hundreds of millions of doses administered so far, yet higher than one in 150,000 previously assumed by some medical authorities, Prof. Greinacher said. Most of the hundreds of people who have been diagnosed recover, but between a fifth and a third have died, and others could suffer permanent consequences.

Data from U.S. and European regulators so far suggest young women are primarily affected by the condition. But several scientists, including Sabine Eichinger, a senior Austrian hematologist who treated one of the first-known patients, have said the correlation could reflect that medical workers and teachers were among the first to get the vaccines in Europe, and the majority of them are younger women.


 

Nemo

Member
Joined
Jul 8, 2019
Messages
2,163
I'm glad all the scientists are having fun, but we're seeing exactly the same clotting problems and immune thrombotic thrombocytopenia from the Pfizer and Moderna vaxxes, which don't contain the adenovirus.
 

grithin

Member
Joined
Jul 1, 2020
Messages
120
has identified more than 1,000 proteins in AstraZeneca’s vaccine derived from human cells

This would not reflect an isolated protein mix; instead, it would seem they are injecting fetal tissue. Injecting non self, human DNA into the blood - aids2 ?
 

PxD

Member
Joined
Aug 13, 2020
Messages
385
It’s the spike proteins produced by the vaccines. They damage vascular endothelial cells, amongst others.
 

StephanF

Member
Joined
Jul 8, 2014
Messages
612
Location
Reno
It’s the spike proteins produced by the vaccines. They damage vascular endothelial cells, amongst others.
Dr. Wolfgang Wodarg also points to the spike protein, he says that there are binding sites on the blood platelets, so whether this stems from a COVID-19 infection, the ‘traditional’ vaccines or the mRNA ‘gene therapy’, all of these produce the spike protein. After it binds to the platelets, clotting can occur.

Here I would strongly recommend using Zeta Aid, it increases the electrostatic repulsion of the blood particles. Maybe, just maybe, it can counter this coagulation triggered by the spike protein.
 

Peatness

Member
Joined
Oct 12, 2020
Messages
11,770
 

aliml

Member
Joined
Apr 17, 2017
Messages
611

Clotting Disorders​

The problem of clots after Covid vaccination was taken more seriously when a preprint paper appeared in Research Square investigating reports “of some vaccine recipients developing unusual thrombotic events and thrombocytopenia”.

The researchers “investigated whether such patients could have a prothrombotic disorder caused by platelet-activating antibodies directed against platelet factor 4 (PF4), as is known to be caused by heparin and sometimes other environmental triggers”.

In short: some of the patients were positive for antibodies to PF4 and the authors concluded that “The AZD1222 [AstraZeneca] vaccine is associated with development of a prothrombotic disorder that clinically resembles heparin-induced thrombocytopenia but which shows a different serological profile”.

They proposed calling this new problem vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). Something tells me that name is going to be changed ASAP.



Aspirin had a preventive effect against all adverse events in anti-PF4/H antibody-positive patients.


Aspirin manifested effects similar to clopidogrel in terms of prevention of thromboses in PF4/H antibody-positive patients, but costs much less and is therefore recommended.

 

Peatness

Member
Joined
Oct 12, 2020
Messages
11,770
 

Similar threads

Top